The study of comparison between MRI diagnosis and clinic on prostatic carcinoma

Objective:Date from magnetic resonance imaging (MRI) on 94 cases were diagnosed prostatic disease by clinic, evaluate the sensitivity 、specificity and accordant rate of MRI diagnosis on prostatic carcinoma; try to improve the diagnostic sensitivity and accordant rate of MRI diagnosis on prostatic carcinoma.Methods:All of the 94 patients were examined by MRI、digit rectum examination (DRE)、B-ultrasonography (B-US) and prostatic-specific antigen (PSA) examination. Using Fast Spin Echo-T 2 weighted imaging(FSE-T 2WI) and Spin Echo-T 1 weighted imaging (SE-T 1WI) pulse sequence in axial orientation as routine in MRI examination, some of them scan with fat-suppression (shot time of inversion recovery, STIR) pulse sequence or in sagittal、coronal orientation additional; The diagnostic results of MRI were compared with that of the other examinations、clinical final diagnosis and the test in parallel.Results:[WT5”BZ]Evaluating the MRI diagnosis on prostatic carcinoma: the sensitivity is 82.69%,the specificity is 90.48%,the likelihood ratio is 8.6827,the accordant rate of diagnosis is 86.17%,Youden's index is 0.7317; evaluating the diagnosis of the test in parallel on prostatic carcinoma: the sensitivity is 98.08%,the specificity is 85.71%,the likelihood ratio is 6.8654,the accordant rate of diagnosis is 92.55%,Youden's index is 0.8379; the sensitivity of diagnosis on prostatic carcinoma is evident different between MRI and the test in parallel by statistic analyse.[WT5”HZ]Conclusion:Different MRI pulse sequence caused different effect on displaying distinct pathologic variety; during scanning and diagnosing of MRI, set proper pulse sequence、 orientation 、parameters, and observe the MRI images carefully, could decrease the supposititious negative rate; combine MRI appearance with clinical information close, making for the diagnosis in differentiating the diversified prostatic diseases; the test in parallel could improve the diagnostic sensitivity on prostatic carcinoma.